This website uses cookies

Read our Privacy policy and Terms of use for more information.




In partnership with

Free, private email, now with 60% off premium this Black Friday.

A private inbox doesn’t have to come with a price tag—or a catch. Proton Mail’s free plan gives you the privacy and security you expect, without selling your data or showing you ads.

Built by scientists and privacy advocates, Proton Mail uses end-to-end encryption to keep your conversations secure. No scanning. No targeting. No creepy promotions.

With Proton, you’re not the product — you’re in control.

Start for free, or upgrade for 60% off this Black Friday. Stay private always.

Support Independent Psychedelic Journalism

Want to financially support original, independent reporting like this? You can! Donate at the link below, or just click the advertisement at the top of this article - no purchases or personal information sharing required

“Three Psychedelic Drug Applications Are at the Food and Drug Administration. For Two of Them, the Clock Was Set by an Office Vacant Since May.”

Psychedelic State(s) of America's Regulatory Dispatch, Vol. V:

By Odette Hauke

PSA’s Regulatory Dispatch, Vol. V: Three Psychedelic Drug Applications Are at the Food and Drug Administration. For Two of Them, the Clock Was Set by an Office Vacant Since May.

PSA’s Regulatory Dispatch, Vol. V: Three Psychedelic Drug Applications Are at the Food and Drug Administration. For Two of Them, the Clock Was Set by an Office Vacant Since May.

Two of the three psychedelic drug applications now at the Food and Drug Administration (FDA) hold a pass that promised a decision in one to two months, but the committee that runs those fast reviews is chaired by a commissioner the Agency has not had since May, and Reuters has reported the program behind the pass was shelved.

That leaves two possible answer dates about five and a half months apart, and both rulebooks converge on a single day, January 15 for Usona and January 22 for Compass, when the written review plan either arrives or the Council has already met and a reader finally learns which clock is running.

On November 9, 2026, Compass Pathways told investors it had finished asking the Food and Drug Administration (FDA) to approve psilocybin, the main psychoactive compound in magic mushrooms, for severe depression. A week earlier, the trade outlet Psychedelic Alpha reported that the Usona Institute, a Wisconsin nonprofit, had asked for the same thing. Both hold a government pass that was supposed to produce an answer in one to two months. By the FDA's own rulebook, the committee that runs those fast reviews is chaired by the FDA commissioner. There has been none since May.

The two clocks are about five and a half months apart, and that gap is the story. If the pass works as advertised, the Agency answers Compass by late January 2027. If it does not, the Agency's deadline is July 8, 2027, and the drug still cannot be dispensed for 90 days after that. For a patient with depression that has not lifted after two or more antidepressants, that is the difference between spring and autumn. For Compass, it is the difference between making the launch it has promised investors and missing it.

Nobody has said which timeline governs. On November 12, 2026, Reuters reported that the FDA had shelved the program behind the pass. A spokesperson for the Department of Health and Human Services, Emily Hilliard, told Reuters the pilot was ongoing and being refined after a public hearing in June. The Agency has published no date for any of the three, and nothing on the record shows either psilocybin review has slowed or any pass was withdrawn.

THE THREE FILES, IN FOUR LINES

  • Three psychedelic applications sit at the FDA. Compass Pathways filed psilocybin for treatment-resistant depression on November 9, 2026. Usona Institute's psilocybin for major depressive disorder was reported on November 2 and is still unconfirmed. Resilient Pharmaceuticals refiled MDMA for post-traumatic stress disorder on a date nobody has published.

  • Two of the three hold a pass that promised an answer in one to two months. All four FDA documents describing that pass say it changes neither the decision nor the standards, and does not guarantee the timing.

  • The ordinary schedule would answer Compass on July 8, 2027, or November 8 without Priority Review. The pass would answer by late January.

  • The FDA has published no date for any of the three.

What the pass was supposed to buy

The Commissioner's National Priority Voucher is a pass the FDA began issuing in 2025 to compress one application's review. The Agency's own page advertises an "Ultra-fast timeline – 1-2 months target vs. 6+ months." Executive Order 14401, signed April 18, 2026, directed the FDA to hand those passes to promising psychedelic drugs, and on April 24 it issued three. Two went to the psilocybin applications now pending. The third went to a drug for post-traumatic stress disorder (PTSD) that has not been filed.

Four published FDA documents describe the program, and every one of them takes the promise back. The fact sheet calls the phases "targets that are intended to be flexible" and says "receipt of a voucher does not impact the likelihood of approval." The program page says the decision "remains with the relevant product Center, using the Center's normal processes." The staff manual guide says selection changes neither review conclusions nor approval standards. The Federal Register notice asks for public comment on the Agency's clarity "regarding the fact that a voucher does not guarantee approval or a 1-2 month timeframe." The holder of a pass has been promised speed it was told in writing not to count on.

The office that runs it is empty

The staff manual guide sets out who decides. A standing panel of senior officials, which the Agency calls the Review Council, discusses each application and votes a recommendation. The guide says plainly: "The FDA Commissioner will serve as Chair of the Council." Nine other seats are named offices, among them the directors of the two centers that review drugs and biological products.

Reuters reported that both of those center directors left the Agency this year and that the Council has gone dormant. The FDA has had no Senate-confirmed commissioner since Marty Makary left in May 2026, and no new drug has been given a pass since. For the nine drugs still in the program, Reuters reported, "FDA career scientists have resumed overseeing review timelines." Rich Danker, a former assistant secretary at that department, said the program was "quietly being phased out."

One case shows what that means. Merck KGaA said in August it held a pass for its fertility drug Pergoveris. Reuters reported the drug "remains unapproved three months after the FDA accepted its final application following an eight-month rolling review." One drug is not a pattern, and it is not one of these three. It is the only published evidence of what the pass has produced lately, and it produced a wait.

The deadline the Agency actually promised

The second clock is written down. The FDA negotiated it with Congress and the drug industry and published it as the Prescription Drug User Fee Act commitment letter. For a drug like Compass's it promises an answer within six months of the filing date if the Agency grants Priority Review, ten months if it does not, and regulation fixes the filing date at 60 days after the application arrives.

Counting from Compass's November 9 submission, those promises fall on July 8, 2027 and November 8, 2027. They are ceilings the Agency set for itself across 90 percent of such applications, not predictions, and Priority Review has not been announced for any of the three.

What each clock produces

Figure 1. What each clock produces: possible FDA answer dates for the Compass and Usona psilocybin applications and the Resilient MDMA application, with ICER's review dates for Compass's drug.

Figure 1. What each clock produces. The two psilocybin applications each carry two possible answer dates about five and a half months apart, depending on whether the fast pass is running. Read down the Compass row: an answer in the shaded window in January, or at the diamond on July 8. The row beneath shows when the Institute for Clinical and Economic Review argues the price, which falls between the two. Shape and fill mark where each date comes from, since the FDA has published none of them. Replaces Figure 1 of Volume III.

The third application has no date at all. The FDA rejected Resilient Pharmaceuticals' MDMA for PTSD on August 9, 2024, and Psychedelic Alpha reported two years later that the company had quietly filed again. A refiling the Agency judges to need a full look restarts a six-month clock, putting an answer on February 9, 2027. That holds only if the FDA took delivery on August 9, 2026, and that day was a Sunday. It is the day a reporter published, not a delivery date. Resilient has never discussed the filing, and the FDA's public database lists only approved drugs, so there is nothing to check.

January 15 and January 22

Two rulebooks, written years apart, put a deadline on the same two days, and those days are when this question stops being open.

The Prescription Drug User Fee Act promises every applicant a letter within 74 calendar days of the application arriving. The letter tells the sponsor how the Agency plans to run the review and whether it expects an advisory committee, the outside panel the FDA sometimes asks to weigh in before deciding. The voucher rules reach the same day. The staff manual guide schedules the Council meeting one to two weeks before the target action date, and the latest meeting that could still deliver the advertised window falls on day 74.

For Usona, whose application was reported as arriving on November 2, day 74 is January 15, 2027. For Compass, it is January 22. On each of those dates the Agency either owes the company a written review plan, meaning the ordinary schedule is running, or the Council has already met, meaning the fast one is. Either way the reader learns which clock governs four months before the price of the drug is argued in public.

The alignment holds only because both rulebooks say what they say. The fact sheet calls the phases flexible, the guide lets any review division ask for more time, and Reuters reported that the two most recent approvals under the program ran past the window anyway. The date is a ceiling, not a promise.

What the gap does to the price, and to the pharmacy

The Institute for Clinical and Economic Review, or ICER, is a Boston nonprofit that estimates what a drug is worth and publishes the price it thinks insurers should pay. It is reviewing Compass's psilocybin now, with an evidence report due May 5, 2027, a panel vote on May 20, and a final report on June 21.

Volume III of this column argued that ICER's vote cannot stop an approval and does not need to, and listed four ways that argument could fail. The first was that an approval might slip past the meeting. In 2024 this same panel judged MDMA with no announced price, and so never voted on whether it was worth its cost. A company with no price cannot be told its price is wrong.

That shield is back in play. On the fast clock, Compass is approved and priced months before ICER publishes anything, and the panel votes on a real number. On the ordinary clock the Agency acts on July 8, 49 days after the vote, and the panel judges a drug with no price. Nothing shows the review has stalled. It no longer needs to.

The gap reaches the pharmacy counter too. Volume II of this column showed that an FDA approval does not by itself let a doctor write the prescription. Under 21 U.S.C. 811(j) the Attorney General has 90 days to move the drug out of Schedule I, and the approval does not take effect until that rule issues. On the fast clock that rule lands in April 2027, inside the launch window Compass has promised investors. On the ordinary clock it lands on October 6, 2027, outside it.

Three things to watch

  1. Whether the FDA gets a confirmed commissioner. The commissioner chairs the Council that decides these fast reviews, and the chair has been empty since May 2026. Until it is filled, the body that is supposed to make these two applications fast has nobody in charge of it.

  2. Compass's letter, due January 22, 2027, and Usona's, due January 15. Each letter says how the Agency plans to run that review. If it arrives describing an ordinary timetable, the fast clock is not running for that drug, and the launch Compass has promised for the first half of 2027 is in doubt.

  3. ICER's revised scoping document, due November 18, 2026. It is the first test of whether the May 20 vote is on schedule. If that vote slips, the price argument moves closer to the approval, and the question of which clock governs stops mattering.

What this does not settle

Usona's filing rests on a single trade report, and neither Usona nor Resilient has discussed its application on the record. The Reuters account rests on six unnamed sources and internal documents against a department denial. Every date here is arithmetic on a published rule, and the dates those rules are counted from are the weak link. Nothing here forecasts an approval.

Author disclosure. Odette Hauke is an epidemiologist and regulatory scientist advising sponsors developing oncology, rare disease and psychedelic drugs, including LSD, MDMA, DMT and ibogaine. She was previously Associate Director of Regulatory Affairs at atai Beckley, which Eli Lilly acquired in September 2026, and a consultant to its ibogaine, R-MDMA and DMT programs.

Related coverage

Enjoyed this column? Subscribe to Psychedelic State(s) of America and share this post with someone who should read it.

Until next time,

The Psychedelic State(s) of America Team

Keep Reading